Developing spatial biology cell and gene therapy applications addresses a question specific to this modality class that conventional small-molecule pharmacology rarely faces so directly. The therapy itself, is a living cell or a genetic payload that must physically reach a specific tissue location and function correctly once there. This makes location not simply an incidental context, but the central variable determining whether a treatment actually works.
Key takeaways
|
Why advanced therapies are spatial problems
A small-molecule drug distributes through tissue according to well-understood pharmacokinetic principles, and its mechanism of action, once bound to a target, is generally independent of exactly which cell in a tissue it happens to be acting on. Cell and gene therapies break that assumption in a specific, consequential way. A CAR T cell is not a molecule diffusing to a target; it is a living cell that must migrate into a tissue, survive there, and remain functionally active specifically at the location where the disease is, and a gene therapy vector must transduce specific cells in a specific tissue compartment to have its intended effect, or its unintended effect if it transduces the wrong cells instead.
That structural difference is why spatial biology, rather than being a nice-to-have addition, is close to a necessary tool for this therapeutic class specifically. Whether the therapy reached the right location, in what quantity, and what it did once there once it arrived are not secondary questions to a cell or gene therapy program; they are close to the entire question a development program needs answered.
Tracking engraftment and persistence
The clearest demonstration that a CAR T cell’s function depends on its specific spatial position, not merely its presence in the tissue at all, comes from a platform built specifically to measure that relationship directly.
The same CAR-T cell type, functioning differently depending on exactly where it sitsA 2021 Scientific Reports paper describes a CAR RNA FISH histo-cytometry platform, combined with an image analysis algorithm, to quantitate the spatial distribution and in vivo functional activity of a CAR T cell population at single-cell resolution directly in tissue. The platform interrogates single-cell expression of multiple messenger RNAs of interest, including CD4, CD8-alpha, interferon gamma, and granzyme B, alongside the CAR construct itself, using probes designed specifically against the CAR’s signaling domain to distinguish it accurately from endogenous sequences. The central finding: CAR T cells in situ exhibited heterogeneous effector gene expression, and this heterogeneity was directly related to distance from tumor cells, allowing a quantitative assessment of a given cell’s potential in vivo effectiveness based specifically on its spatial position. That is a direct, single-cell-resolution answer to a question flow cytometry or bulk sequencing cannot address: two CAR T cells with identical genetic engineering can be functioning completely differently depending on nothing more than where in the tissue each one happens to sit. |
Biodistribution in tissue
Where an engineered cell physically ends up within a tissue, not just whether it is present anywhere in the organ, has a direct bearing on whether it can actually reach and act on its target.
A multimodal imaging study combining three-dimensional micro-computed tomography bioluminescence tomography, light-sheet fluorescence microscopy, and cyclic immunofluorescence staining, applied to CAR T cell therapy against a solid tumor xenograft, found that CAR T cells predominantly accumulated at the tumor periphery and around blood vessels specifically, rather than distributing evenly throughout the tumor mass. That spatial pattern is directly relevant to one of solid tumor CAR-T therapy’s most persistent challenges: a cell population concentrated at the periphery, rather than penetrating to the tumor core, has limited opportunity to act on tumor cells sitting deeper within the mass, regardless of how many CAR T cells were administered or how well they function where they do reach.
The same study found a second, distinct finding with direct dosing implications: local interleukin-2 administration produced increased CAR T cell proliferation in the early treatment phase, but sustained, long-term overstimulation of the cells that ultimately negated the initial therapeutic benefit. That is a spatially localized dosing consequence, tied specifically to where and how a supporting cytokine was administered relative to the engineered cells, that a systemic pharmacokinetic measurement of the cytokine alone would not have revealed as clearly, since the relevant effect depends on local concentration and cellular exposure history, not systemic drug level.
Local response and toxicity
The same location-matters principle established for CAR-T cell function applies directly to gene therapy safety assessment, a different modality within this same therapeutic class facing a structurally similar spatial question.
This section’s hub, Where spatial biology is headed in drug discovery, covers a 2025 study that used single-cell and spatial transcriptomics to map gene therapy-associated retinal inflammation in non-human primates following subretinal AAV administration, finding that the treatment activates microglia and drives their migration to the subretinal space, where monocyte-derived signaling recruits a chronic T cell-mediated antiviral response. That finding is not repeated in detail here; the relevant point for this spoke is that the same underlying question, exactly which cells, in exactly which tissue compartment, drive a therapy’s local effect, applies with equal force to cell therapy function and to gene therapy safety, despite these being structurally different treatment modalities within the same broader therapeutic class.
Modality | Spatial question | Finding |
CAR T cell therapy | Does function depend on tissue position | Effector gene expression heterogeneity directly related to distance from tumor cells |
CAR T cell therapy | Where do cells physically accumulate | Predominant accumulation at tumor periphery and around vessels, not evenly through the tumor |
AAV gene therapy | Which cells drive a treatment-associated side effect | Microglia activation and migration recruiting a chronic T cell-mediated response, covered in this section’s hub |
Table 1. The same underlying spatial question, exactly where a therapy or its effect is located within tissue, recurs across structurally different cell and gene therapy modalities.
Emerging spatial readouts
Beyond the observational spatial methods described above, a genuinely functional spatial genomics approach is a plausible emerging readout specifically for cell therapy potency and functional assessment.
This section’s hub covers Perturb-FISH, a method combining pooled CRISPR perturbation screening with spatially resolved transcriptomics, in the context of basic discovery research. The same underlying capability, testing how a genetic perturbation affects a cell’s function and its interaction with physically neighboring cells simultaneously, is a plausible fit for cell therapy manufacturing and quality assessment specifically: rather than only confirming a manufactured cell product’s genetic modification is present, a functional spatial readout could in principle test how engineered cells actually behave once placed in a tissue-like context alongside target cells, closer to the in vivo condition a potency assay is meant to predict than a purely in vitro functional test achieves.
The broader immunological principles connecting immune cell spatial behavior to disease and treatment outcome, developed for endogenous autoimmune and inflammatory disease rather than engineered cellular products specifically, are covered in Spatial Biology in Immunology and Autoimmune Disease. For where cell and gene therapy sits within spatial biology’s broader emerging trajectory, see Where Spatial Biology is Headed in Drug Discovery, and for where this fits within the full spatial biology pipeline, Spatial Biology in Drug Discovery: From Target Discovery to Translational Medicine.
This article was produced under Drug Discovery News’s AI editorial policies.
